RT Journal Article
SR Electronic
T1 Spread of SARS-CoV-2 Delta variant infections bearing the S:E484Q and S:T95I mutations in July and August 2021 in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263371
DO 10.1101/2021.09.13.21263371
A1 Verdurme, Laura
A1 Danesh, Gonché
A1 Trombert-Paolantoni, Sabine
A1 Sofonea, Mircea T.
A1 Noel, Valérie
A1 Foulongne, Vincent
A1 Montès, Brigitte
A1 Tuaillon, Edouard
A1 Haim-Boukobza, Stéphanie
A1 Roquebert, Bénédicte
A1 Alizon, Samuel
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263371.abstract
AB Analysing 92,598 variant screening tests performed on SARS-CoV-2 positive samples collected in France between 1 July and 31 August 2021 shows an increase of Kappa-like infections. Full genome sequencing reveals that these correspond to Delta variants bearing the S:E484Q mutation. Most of these sequences belong to a phylogenetic cluster and also bear the S:T95I mutation. Further monitoring is needed to determine if this trend is driven by undocumented superspreading events or an early signal of future viral evolutionary dynamics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementThis study was partly funded by the Region Occitanie and the ANR (PhyEpi project).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Institutional Review Board of the CHU of Montpellier.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available after the peer-review process.